Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD

Blood (2019) 134 (Supplement_1): 1869.

https://doi.org/10.1182/blood-2019-121805

Published: 2019

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 3518.

https://doi.org/10.1182/blood-2019-126509

Published: 2019

Journal Articles

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Amer M. Zeidan, MBBS, MHS, Daniel J. DeAngelo, MD PhD, Jeanne M. Palmer, Christopher S. Seet, MD PhD, Martin S. Tallman, MD, Xin Wei, PhD, Ying Fei Li, PhD, Nanette Hock, RN, MSN, Michael R. Burgess, Kristen Hege, Wendy Stock, MD

Blood (2019) 134 (Supplement_1): 1320.

https://doi.org/10.1182/blood-2019-125363

Published: 2019

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Blood (2019) 134 (Supplement_1): 285.

https://doi.org/10.1182/blood-2019-126977

Published: 2019

Journal Articles

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Xinxin Cao, Jian Li, MD, Ai-lin Zhao, Xue-min Gao, Hua-cong Cai, MD, Lu Zhang, MD, Yan Zhang, MD, Jun Feng, MD, Miao Chen, MD, Tie-nan Zhu, MD, Na Niu, Jian Sun, MD, Zhi-yong Liang, MD, Dao-Bin Zhou, Ming-hui Duan, MD

Blood (2019) 134 (Supplement_1): 294.

https://doi.org/10.1182/blood-2019-122220

Published: 2019

Journal Articles

Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)

Tamara P. Miller, MD MSc, Kelly D Getz, Biniyam Demissei, MD PhD, Karen R. Rabin, MD PhD, Marla Daves, MD, Philip J. Lupo, PhD MPH, Michael E. Scheurer, PhD MPH, Evanette Burrows, MPH, Brian T. Fisher, DO, MSCE, Robert W. Grundmeier, MD, Judy Lee, Jennifer J. Wilkes, MDMSCE, Lena E. Winestone, MD, Maria Monica J. Gramatges, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 333.

https://doi.org/10.1182/blood-2019-130656

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4006.

https://doi.org/10.1182/blood-2019-121936

Published: 2019

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Naoto Takahashi, MD PhD, Itaru Matsumura, MD PhD, Shin Fujisawa, MD, Kenichi Ishizawa, MD PhD, Takaaki ONO, MD PhD, Emiko Sakaida, MD PhD, Naohiro Sekiguchi, MD PhD, Yusuke Tanetsugu, Kei Fukuhara, Masayuki Ohkura, Yuichiro Koide, Masayuki Hino, MD PhD

Blood (2019) 134 (Supplement_1): 4159.

https://doi.org/10.1182/blood-2019-121809

Published: 2019

Journal Articles

Efficacy and Safety of Eltrombopag in Chinese Patients with Chronic Immune Thrombocytopenia: Stage 2 Results from a Multicenter Phase III Study

Renchi Yang, MD, Liu Xiaofan, MD, Junmin Li, MD, Ming Hou, MD PhD, Jin Jie, MD, Meijuan Huang, MD, Ziqiang Yu, PhD, Xiaojun Xu, MD PhD, Xiaohui Zhang

Blood (2018) 132 (Supplement 1): 3760.

https://doi.org/10.1182/blood-2018-99-110501

Published: 2018

Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD

Blood (2018) 132 (Supplement 1): 353.

https://doi.org/10.1182/blood-2018-99-111338

Published: 2018

Journal Articles

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Mehdi Hamadani, MD, Graham P. Collins, MB BS DPhil, Felipe Samaniego, MD, Alexander I Spira, MD, Andrew Davies, John Radford, MD FRCP, Paolo Caimi, MD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Steven M. Horwitz, MD

Blood (2018) 132 (Supplement 1): 928.

https://doi.org/10.1182/blood-2018-99-118198

Published: 2018

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Oliver Meyer, James B. Bussel, MD, Raymond S Wong, MBChB, MD, Abderrahim Khelif, Miona Stankovic, Joan Maier, Mansoor N. Saleh

Blood (2018) 132 (Supplement 1): 1152.

https://doi.org/10.1182/blood-2018-99-114694

Published: 2018

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Blood (2018) 132 (Supplement 1): 1306.

https://doi.org/10.1182/blood-2018-99-112478

Published: 2018

Journal Articles

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Hwang Wen-Li, MD, Shao-Min Han, MD, Shyuann-Yuh Lin, MD, Ming-Chih Chang, MD, Li-Yuan Bai, PhD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, Yeu-Chin Chen, MD, Ta-Chih Liu, MD PhD, Po-Nan Wang, MD, Jyh-Pyng Gau, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, Jih-Luh Tang, MD

Blood (2018) 132 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2018-99-112342

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2018-99-113111

Published: 2018

Journal Articles

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Tim H. Brummendorf, MD, Carlo Gambacorti-Passerini, MD, Andreas Hochhaus, MD, Jeff H. Lipton, MD PhD, Vamsi Kota, MBBS, Michael W. Deininger, MD PhD, Eric Leip, PhD, Andrea Viqueira, MD, Roxanne Ferdinand, MBBS MFPM, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3005.

https://doi.org/10.1182/blood-2018-99-110543

Published: 2018

Journal Articles

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, FRACP, FRCPA, Judith Trotman, MBChB, FRACP, FRCPA, James Hilger, Xiaoping Zhang, Shibao Feng, PhD, Sunhee Ro, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 4057.

https://doi.org/10.1182/blood.V130.Suppl_1.4057.4057

Published: 2017

NARROW

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Efficacy and Safety of Eltrombopag in Chinese Patients with Chronic Immune Thrombocytopenia: Stage 2 Results from a Multicenter Phase III Study

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

NOVEL-1 st : Interim Analysis of a Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only